Pharmacokinetic Characteristics of a Nifedipine and Lidocaine Fixed Combination in the Form of Rectal Cream: Two Decades Data Analysis

Authors

  • Raffaele Ottaiano New.Fa.Dem., S.r.l., Italy
  • Mara Sebastiano New.Fa.Dem., S.r.l., Italy
  • Larysa Bondarenko Institute of Pharmacology & Toxicology of NAMS of Ukraine, SI, Ukraine https://orcid.org/0000-0001-5107-8148
  • Oleksandra Iudina UA PRO-PHARMA, LLC, Ukraine

DOI:

https://doi.org/10.20535/ibb.2021.5.1.227361

Keywords:

nifedipine, lidocaine, fixed combination, pharmacokinetic characteristics

Abstract

The creation of medicines' fixed combinations from compounds with complementary effects is one of the most popular directions in modern pharmacology and pharmaceutics. In case of nifedipine and lidocaine fixed combination such approach is quite obvious. The present review article is devoted to the analysis of clinical and non-clinical studies results on the assessment of the pharmacokinetic characteristics of these medicines. Although the oral route is the most convenient for drug administration, there are a number of circumstances where this is not possible from either a clinical or pharmaceutical perspective. In these cases, the rectal route may represent a practical alternative and can be used to administer drugs for both local and systemic actions. Research data of last decades suggested that nifedipine, a calcium channel blocker, could be effective in reducing anal resting pressure and in healing chronic anal fissure and acute thrombosed hemorrhoids. Another component of fixed combination lidocaine is a local anesthetic usually used to relieve pain of anal fissures and symptomatic hemorrhoids. In combinations lidocaine and nifedipine have complementary actions. Analysis of all available studies (during last 2 decades) which were aimed to investigate pharmacokinetic characteristics of a nifedipine and lidocaine fixed combination in the form of rectal cream showed that following topical application, the active ingredients nifedipine and lidocaine are absorbed into the bloodstream in only small quantities that have no major implications for the safety of the product, and systemic absorption, if any, was incomparably lower than absorption following per os administration of the two active ingredients.

References

Hua S. Physiological and pharmaceutical considerations for rectal drug formulations. Front Pharmacol. 2019;10:1196. DOI: 10.3389/fphar.2019.01196

Purohit TJ, Hanning SM, Wu Z. Advances in rectal drug delivery systems. Pharm Dev Technol. 2018 Dec;23(10):942-52. DOI: 10.1080/10837450.2018.1484766

Lowry M. Rectal drug administration in adults: how, when, why. Nurs Times. 2016 Feb 24-Mar 1;112(8):12-4.

van Hoogdalem E, de Boer AG, Breimer DD. Pharmacokinetics of rectal drug administration, Part I. Clin Pharmacokinet. 1991 Jul;21(1):11-26. DOI: 10.2165/00003088-199121010-00002

Salem AE, Mohamed EA, Elghadban HM, Abdelghani GM. Potential combination topical therapy of anal fissure: develop-ment, evaluation, and clinical study. Drug Deliv. 2018 Nov;25(1):1672-82. DOI: 10.1080/10717544.2018.1507059

Guideline on clinical development of fixed combination medicinal products – Revision 2 (EMA/CHMP/158268/2017). European Medicines Agency; 2017. 12 p.

Equivalence studies for the demonstration of therapeutic equivalence for locally applied, locally acting products in the gastrointestinal tract (CPMP/EWP/239/95 Rev. 1, Corr. 1). European Medicines Agency; 2019. 13 p.

ICH Topic E 3. Structure and content of clinical study reports. Step 5. Note for guidance on structure and content of clinical study reports (CPMP/ICH/137/95). European Medicines Agency; 1996. 48 p.

Guideline on the investigation of bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/Corr). European Medicines Agency; 2010. 27 p.

Teimouri A. Extemporaneously compounded topical calcium channel blockers for wounds and skin ulcers [MSc thesis]. Nova Scotia: Dalhousie University Halifax; 2019.

Carapeti EA, Kamm MA, Evans BK, Phillips RK. Topical diltiazem and bethanechol decrease anal sphincter pressure without side effects. Gut. 1999 Nov;45(5):719-22. DOI: 10.1136/gut.45.5.719

Cook TA, Branding AF, Mortensen NJ. The pharmacology of the internal anal sphincter and new treatments of ano-rectal disorders. Aliment Pharmacol Ther. 2001 Jul;15(7):887-98. DOI: 10.1046/j.1365-2036.2001.00995.x

Chrysos E, Xynos E, Tzovaras G, Zoras OJ, Tsiaoussis J, Vassilakis SJ. Effect of nifedipine on rectoanal motility. Dis Colon Rectum. 1996 Feb;39(2):212-6. DOI: 10.1007/BF02068078

Antropoli C, Perrotti P, Rubino M, Martino A, De Stefano G, Migliore G, et al. Nifedipine for local use in conserva¬tive treatment of anal fissures: preliminary results of a multicenter study. Dis Colon Rectum. 1999 Aug;42(8):1011-5. DOI: 10.1007/BF02236693

Ezri T, Susmallian S. Topical nifedipine vs. topical glyceryl trinitrate for treatment of chronic anal fissure. Dis Colon Rectum. 2003 Jun;46(6):805-8. DOI: 10.1007/s10350-004-6660-8

Perrotti P, Antropoli M, Noschese G, Bartone G, De Stefano G, Pacifico F, et al. Topical nifedipine(®) for conservative treatment of acute hemorrhoidal thrombosis. Colorectal Dis. 2000 Jan;2(1):18-21. DOI: 10.1046/j.1463-1318.2000.00130.x

Gough MJ, Lewis A. The conservative treatment of fissure-in-ano. Br J Surg. 1983 Mar;70(3):175-6. DOI: 10.1002/bjs.1800700312

Jonas M, Neal KR, Abercrombie JF, Scholefield JH. A randomized trial of oral vs. topical diltiazem for chronic anal fissures. Dis Colon Rectum. 2001 Aug;44(8):1074-8. DOI: 10.1007/BF02234624

Kujur ADS, Paul Ekka NM, Chandra S, Lal S, Malua S. Comparative study to assess the effectiveness of topical nifedi-pine and diltiazem in the treatment of chronic anal fissure. J Family Med Prim Care. 2020 Nov 30;9(11):5652-7. DOI: 10.4103/jfmpc.jfmpc_986_20

Neiger A, Herms E. The symptomatic therapy of hemorrhoids and anal eczema — a report of experiences from proctology practice. Schweiz Rundsch Med Prax. 1990 Aug 2;79(31-32):918-20.

Cook TA, Brading AF, Mortensen NJ. Effects of nifedipine on anorectal smooth muscle in vitro Dis Colon Rectum. 1999 Jun;42(6):782-7. DOI: 10.1007/BF02236936

Cook TA, Brading AF, Mortensen NJ. Differences in contractile properties of anorectal smooth muscle and the effects of calcium channel blockade. Br J Surg. 1999 Jan;86(1):70-5. DOI: 10.1046/j.1365-2168.1999.00998.x

Perrotti P, Bove A, Antropoli C, Molino D, Antropoli M, Balzano A, et al. Topical nifedipine with lidocaine ointment vs. active control for treatment of chronic anal fissure: results of a prospective, randomized, double-blind study. Dis Colon Rectum. 2002 Nov;45(11):1468-75. DOI: 10.1007/s10350-004-6452-1

Perrotti P, Antropoli C, Molino D, De Stefano G, Antropoli M. Conservative treatment of acute thrombosed external hemorrhoids with topical nifedipine. Dis Colon Rectum. 2001 Mar;44(3):405-9. DOI: 10.1007/BF02234741

Nelson RL, Manuel D, Gumienny C, Spencer B, Patel K, Schmitt K, Castillo D, Bravo A, Yeboah-Sampong A. A systematic re¬view and meta-analysis of the treatment of anal fissure. Tech Coloproctol. 2017 Aug;21(8):605-625. DOI: 10.1007/s10151-017-1664-2

Perrotti P, Dominici P, Grossi E, Antropoli C, Giannotti G, Cusato M, et al. Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. Clin Drug Investig. 2009;29(4):243-56. DOI: 10.2165/00044011-200929040-00003

Perrotti P, Grumetto L, Barbato F, Antropoli C. Serum levels and possible haemodynamic effects following anorectal application of an ointment containing nifedipine and lignocaine: a study in healthy volunteers. Clin Drug Investig. 2006;26(8):459-67. DOI: 10.2165/00044011-200626080-00004

Raemsch KD, Sommer J. Pharmacokinetics and metabolism of nifedipine. Hypertension. 1983 Jul-Aug;5(4 Pt 2):II18-24. DOI: 10.1161/01.hyp.5.4_pt_2.ii18

Traube M, Hongo M, McAllister RG Jr, McCallum RW. Correlation of plasma levels of nifedipine and cardiovascular effects after sublingual dosing in normal subjects. J Clin Pharmacol. 1985 Mar;25(2):125-9. DOI: 10.1002/j.1552-4604.1985.tb02812.x

Kurosawa S, Kurosawa N, Owada E, Matsuhashi N, Ito K. Rectal administration of nifedipine: hemodynamic effects and pharmacokinetics in hypertensives. J Int Med Res. 1987 May-Jun;15(3):121-7. DOI: 10.1177/030006058701500301

Kleinbloesem CH, van Harten J, de Leede LG, van Brummelen P, Breimer DD. Nifedipine kinetics and dynamics during rectal infusion to steady state with an osmotic system. Clin Pharmacol Ther. 1984 Sep;36(3):396-401. DOI: 10.1038/clpt.1984.194

Covino BG. Toxicity of local anesthetic agents. Acta Anaesthesiol Belg. 1988;39(3 Suppl 2):159-64.

Tucker GT, Mather LE. Clinical pharmacokinetics of local anesthetics. Clin Pharmacokinet. 1979 Jul-Aug;4(4):241-78. DOI: 10.2165/00003088-197904040-00001

Echizen H, Eichelbaum M. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinet. 1986 Nov-Dec;11(6):425-49. DOI: 10.2165/00003088-198611060-00002

Covino BG. Pharmacology of local anesthetics. Br J Anaesth. 1986 Jul;58(7):701-16. DOI: 10.1093/bja/58.7.701

Tonsuwannont W, Praisontarangkul OA, Manorot M, Klangwarnwong D. Pharmacokinetics of oral lidocaine and nifedipine in patients with liver cirrhosis. J Med Assoc Thai. 1996 May;79(5):309-19.

Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, editors. Goodman & Gilman's the pharmacological basis of therapeu-tics. 9th ed. New York: McGraw-Hill; 1996. p. 1754-65.

Shiau JM, Su HP, Chen HS, Hung KC, Lin SE, Tseng CC. Use of a topical anesthetic cream (EMLA) to reduce pain after hemorrhoidectomy. Reg Anesth Pain Med. 2008 Jan-Feb;33(1):30-5. DOI: 10.1016/j.rapm.2007.07.012

Vickers ER, Marzbani N, Gerzina TM, McLean C, Punnia-Moorthy A, Mather L. Pharmacokinetics of EMLA cream 5% application to oral mucosa. Anesth Prog. 1997 Winter;44(1):32-7.

Leopold A, Wilson S, Weaver JS, Moursi AM. Pharmacokinetics of lidocaine delivered from a transmucosal patch in children. Anesth Prog. Summer 2002;49(3):82-7.

Jensen SL. Treatment of first episodes of acute anal fissure: prospective randomised study of lignocaine ointment versus hydrocortisone ointment or warm sitz baths plus bran. Br Med J (Clin Res Ed). 1986 May 3;292(6529):1167-9. DOI: 10.1136/bmj.292.6529.1167

McDonald P, Driscoll AM, Nicholls RJ. The anal dilator in the conservative management of acute anal fissures. Br J Surg. 1983 Jan;70(1):25-6. DOI: 10.1002/bjs.1800700109

Havlickova B, Weyandt GH. Therapeutic management of anal eczema: an evidence-based review. Int J Clin Pract. 2014 Nov;68(11):1388-99. DOI: 10.1111/ijcp.12457

Brown AC, Sumfest JM, Rozwadowski JV. Histopathology of the internal anal sphincter in chronic anal fissure. Dis Colon Rectum. 1989 Aug;32(8):680-3. DOI: 10.1007/BF02555773

Benfeldt E, Serup J, Menné T. Effect of barrier perturbation on cutaneous salicylic acid penetration in human skin: in vivo pharmacokinetics using microdialysis and non-invasive quantification of barrier function. Br J Dermatol. 1999 Apr;140(4):739-48. DOI: 10.1046/j.1365-2133.1999.02859.x

Misra MC, Imlitemsu. Drug treatment of haemorrhoids. Drugs. 2005;65(11):1481-91. DOI: 10.2165/00003495-200565110-00003

Nisar PJ, Scholefield JH. Managing haemorrhoids. BMJ. 2003 Oct 11;327(7419):847-51. DOI: 10.1136/bmj.327.7419.847

Wynn T. Case report: wound care of a diabetic foot ulcer. Int J Pharm Compd. 2004;8(4):265-7.

Santis AK, De Freitas Z, Maria F, Ricci-Junior E, De Brito-Gitirana L, Fonseca LB, et al. Nifedipine in semi-solid formulations for topical use in peripheral vascular disease: preparation, characterization, and permeation assay. Drug Dev Ind Pharm. 2013 Jul;39(7):1098-106. DOI: 10.3109/03639045.2012.711833

Torsiello MJ, Kopacki MH. Transdermal nifedipine for wound healing: case reports. Int J Pharm Compd. 2000 Sep-Oct;4(5):356-8.

Linares-Gil MJ, Valls J, Hereu-Boher P, Nebot FJ, De-Ramón B, Diaz-Munió E, et al. Topical analgesia with lidocaine plus diclofenac decreases pain in benign anorectal surgery: Randomized, double-blind, and controlled clinical trial. Clin Transl Gastroenterol. 2018 Nov 23;9(11):210. DOI: 10.1038/s41424-018-0075-7

Phoenix™ Dry Heat Systems [Internet]. Synersy.fr. 2021 [cited 2021 Feb 10]. Available from: http://www.synersy.fr/99310067-Rev.-04-18-Phoenix-Diffusion-Testing-Systems.pdf

Thakker K, Chern W. Development and validation of in vitro release tests for semisolid dosage forms—case study. Dissolution Technologies. 2003;10(2):10-5. DOI: 10.14227/DT100203P10

Validation of analytical procedures: Text and methodology Q2(R1). [Internet]. Database.ich.org. 2021 [cited 2021 Feb 10]. Available from: https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf

Downloads

Published

2021-04-06

How to Cite

1.
Ottaiano R, Sebastiano M, Bondarenko L, Iudina O. Pharmacokinetic Characteristics of a Nifedipine and Lidocaine Fixed Combination in the Form of Rectal Cream: Two Decades Data Analysis. Innov Biosyst Bioeng [Internet]. 2021Apr.6 [cited 2021Oct.23];5(1):27-36. Available from: http://ibb.kpi.ua/article/view/227361

Issue

Section

Articles